EntreMed’s ENMD-2076 Demonstrates Significant Anti-Cancer Activity in Multiple Myeloma Preclinical Models
EntreMed, Inc. , today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Â Results of the study, conducted by EntreMed’s collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University …

Read more on PR Newswire via Yahoo! Finance